Format

Send to

Choose Destination
Pediatrics. 2006 Aug;118(2):e506-8. Epub 2006 Jun 30.

Topical voriconazole solution for cutaneous aspergillosis in a pediatric patient after bone marrow transplant.

Author information

1
Clinical Sciences Division, University of Michigan College of Pharmacy and Health System, Ann Arbor, Michigan, USA. kriklein@umich.edu

Abstract

Invasive aspergillosis seems to be on the rise, especially in immunocompromised children. Historically, only systemic amphotericin B has been effective against Aspergillus. Development of newer antifungal agents, such as voriconazole and caspofungin, has improved the treatment options available for aspergillosis, although no definitive management strategy has been established. Here we describe the use of topical voriconazole combined with systemic antifungal agents for cutaneous aspergillosis in a pediatric patient after bone marrow transplant.

PMID:
16816005
DOI:
10.1542/peds.2005-2213
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center